Breaking News
Investing Pro 0
🚨 Our Pro Data Reveals the True Winner of Earnings Season Access Data

Biotech-for-hire PeptiDream charts new path and becomes short target

Stock Markets Nov 13, 2019 10:48AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. Patrick Reid, President and CEO of PeptiDream Inc, talks with a researcher at the company's laboratory in Kawasaki, Japan
 
BAYGN
-0.67%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
AMGN
-3.87%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
BMY
-1.43%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Rocky Swift

TOKYO (Reuters) - The promise of PeptiDream Inc's drug-discovery technology and its lucrative research-for-hire contracts have made it a darling of the Tokyo stock market. Now, those gains have made it a target for short-seller Muddy Waters.

The company, which has seen its market value jump fivefold to $6 billion over the past four years, is now pivoting its strategy to in-house research, using its technology that allows it to create libraries of peptide chemicals that can bind drugs to cells.

Muddy Waters Capital LLC says that the biotech company's new, and traditional, businesses are flawed and is betting its shares will fall back to earth as a result.

Since its listing in 2013, PeptiDream has grown from a lab start-up into a company with the highest profit margins in the Japanese pharmaceutical industry - without ever having brought a drug to market. Its technology has attracted a bevy of partners including Novartis AG, Merck & Co and Shionogi & Co.

"We're on the cusp of over the next 1-5 years of introducing a multitude of drugs into the clinic through our big pharma and strategic partnerships," PeptiDream President Patrick Reid told Reuters in an interview.

"We'd rather get 5% of 100 drugs than get 100% of five drugs," he said. He estimates that around half of all drugs being worked on by PeptiDream partners are cancer drugs.

PeptiDream's rocketing market value has been helped by its traditional fees for collaborating in R&D and licensing deals to use its libraries. Its operating profit margin is 50%, the highest of all 37 members in the Tokyo market's pharma index, where the average is 14%.

MUDDY WATERS DEALS DISPUTE

However the shares of the Kawasaki-based company fell 4 percent on the Nov. 7 release of Muddy Water's report, which doubted the viability of many of its existing partnerships and said investors were "deluded as to its potential for commercializing drugs".

"There's real technology there, but it's the usefulness of the technology that we question," Muddy Waters founder Carson Block said in an interview with Reuters. "It's cool, but so far it's been unable to yield anything that's meaningful."

PeptiDream was now "massively overvalued", Block said, adding that "many of these partnerships that are the basis of this valuation seem inactive".

PeptiDream's Reid declined to comment on the Muddy Waters report, referring to a company statement that "completely rejects" the short-seller's assertions.

The company says it has 19 discovery and development partners, predominantly big to mid pharma firms. Among its 101 programs in progress, compared with 60 in 2017, two are cancer-related compounds being developed with Bristol-Myers Squibb (NYSE:BMY) now in phase 1 clinical studies.

Twelve of PeptiDream's partners told Reuters their partnerships were active and ongoing, including pharma giants Bristol-Myers, Merck, Novartis, Bayer AG (DE:BAYGN) and Amgen Inc (NASDAQ:AMGN).

Japan's Mitsubishi Tanabe Pharma Corp declined to comment on the status of its relationship. The other six companies did not respond to multiple requests for comment.

Block declined to name a price target for PeptiDream or the size of its short strategy, which pays off when a stock falls.

PeptiDream's shares are trading about 5% lower than before the release of Block's report. PeptiDream is the second short play in Japan for Muddy Waters, which became famous for its bearish calls on Chinese companies. Muddy Waters announced a short bet on Nidec Corp in December 2016. Shares in the maker of precision motors have since risen more than 60%.

"It's a bunt single, and that's better than a strikeout," Block said of PeptiDream's share fall, referring by bunt single to a baseball play that sees a batter eke out a small gain.

"Japan's potentially interesting. We might look to come back and hit some more bunt singles and see if we can build up a brand."

PROTEIN HULA HOOPS

PeptiDream's research partners do the heavy lifting in bringing drugs through clinical trials to market - allowing the company to avoid much of the large development costs and risks.

Even so, as the company increasingly looks to keep some ownership of its research, it will still receive future milestone payments and royalties.

On top of its research partnerships, it also has seven license agreements for its library or drug-discovery platform.

PeptiDream concentrates on "constrained peptides", particularly macrocyclic peptides - hula hoops of natural and non-natural amino acids that can carry various cargoes to specific types of cells - such as cancer or inflamed tissue.

Founded in 2006, the company sprang out of the research of University of Tokyo professor Hiroaki Suga. Suga looked to Reid, then an associate professor at the university, to help forge the connections to big pharma.

As discoveries related to antibody and small-molecule treatments dwindle, peptide-based compounds are likely to become increasingly important as a class of drugs, said Bernstein analyst Shen He, who has an "outperform" on the stock.

"PeptiDream is one of the best technology platforms out there to solve this," He said. "But it's not an overnight journey."

Japan Pharma Stock Performance - https://fingfx.thomsonreuters.com/gfx/mkt/12/8572/8497/japan%20pharma%20stocks.jpg

Biotech-for-hire PeptiDream charts new path and becomes short target
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email